About Curasight

First-in-Class Radioligand Therapy Targeting uPAR – the Driver of Cancer Aggressiveness

Curasight is a clinical stage radiopharmaceutical company pioneering a new class of radioligand therapy uTREAT® that targets uPAR, a key functional driver of cancer invasion, angiogenesis, and metastasis. Contrary to other RLT targets, uPAR is upregulated across all aggressive solid tumors.

uPAR is also an ideal target for radiolabeled imaging enabling 100% match between diagnostic and treatment. Companion diagnostic uTRACE® is fully developed and GMP manufactured and validated in 9 clinical trials in different solid tumors (450 patients).

By selectively eradicating the most aggressive cancer cells and their supportive microenvironment, our uPAR-targeted theranostic platform enables precise, personalized, and pan-tumor cancer treatment (>85% of solid tumors).

One target. One therapy. A pipeline-in-a-drug for aggressive solid tumors.

Mission

Curasight's mission is to build leadership in precision oncology by pairing uPAR imaging and radioligand therapy to identify, target, and eliminate aggressive solid tumors with unmatched precision - across multiple indications.

One Target. One Drug. Across aggressive solid tumors